Treatment with a 25-mer peptide targeting the MARCKS phosphorylation site domain (MPS peptide) suppressed tumor growth and metastasis in vivo, reduced levels of phospho-MARCKS and PIP3, and enhanced the sensitivity of lung cancer cells to erlotinib treatment in vitro and in vivo. The gene discussed is MARCKS; the disease is neoplasm.